About Genconn

Genconn Biotech is fully owned by Healthconn, a subsidiary of Foxconn. Our core Business covering categories such as molecular biology and genomics, functional medicine, and integrated food safety services. We are actively engaging collaboration and interaction with both domestic and international molecular biotechnologies. With the foundation on the examination technologies of food and functional medicine, we are pursuing vigorous actions to broaden the applications on molecular genomics.

With regard to the test via molecular genomic technologies, we are frequently recognized and have collaborated with global biotech companies. For example, we are the exclusive dealer in Taiwan for Guardant Health who is a renowned cancer liquid biopsy company in US. We provide Guardant 360 test for advanced cancer patients, with an aim to screen gene mutation in tumors of the relapsed cancer, for the assessment of best therapy.

 

On top of incorporate world class cutting age technologies, we have constantly launched in-house developed products to screen cancer genes. Our solutions for gene screening targeted on tumor tissues and liquid biopsy, focused on the clinical diagnosis of lung cancer and colorectal cancer, assessment and follow-up on the relapsed cases. The objective is to assist clinical physicians to make treatment decision which can provide maximum benefit to cancer patients.


Undertook Foxconn' s broad and in-depth global layout capabilities, taking a preventive measurement to counterattack diseases. We started from detection to customized monitoring, risk assessment, and big data integration. In the future, we will develop early cancer diagnosis and detection plus companion diagnostic technology with international biotechnology companies. Meanwhile, we also aim to establish a detection platform with Chinese gene specificity. We are looking forward to accelerate the applied research on human medicine and genetic analysis through our expertise.

    Core Advantages

    Recognized and Collaborate with Global Biotech Companies to Lead the Technologies of Molecular Diagnosis in Taiwan

    This is a convergence of multi-disciplinary talents across the nations, together with the collaboration among industry, academic, research institutes, and the power of innovation. We are actively engaging collaboration and interaction with major multinational biotech companies, and incorporate world class advanced diagnosis platform. Our objective is to synchronize molecular diagnosis technology in Taiwan with the advanced nations around the world. Taking foothold in Taiwan, we dedicated ourselves to major fields in diagnosis and prevention of cancers.

    Synergy with the Resource and Service Chain from the Parent Company to Provide a Comprehensive Vertical Service for the Industry Chain NEXT
    Core Advantages

    Synergy with the Resource and Service Chain from the Parent Company to Provide a Comprehensive Vertical Service for the Industry Chain

    Synergy with the professional resource and service chain from parent company -Healthconn. Based on individual unique gene, environment and life style to decipher digital code, then further develop precision and personalized medical standard. Integrate resources to provide following services in accordance with customer demand: Technology development, clinical trial, health management, plus early prevention and diagnosis of cancer. Provide a comprehensive service to satisfy customer demand.

    Recognized and Collaborate with Global Biotech Companies to Lead the Technologies of Molecular Diagnosis in Taiwan BACK